Novel Medications in the Treatment of Atrium Fibrillation

Objective & Hypothesis: Atrial fibrillation (AF) is the most commonly encountered arrhythmia.

📊

Key Findings & Data:Besides serious health problems and mortality incurred by patients, its complitacions bring about substantial economical losses.

💡

Conclusion & Impact:This paper reviews novel medicaitons in AF treatment.

🔬Design:Review & Systematic Survey

📍Scope:Comprehensive Sample

⚙️Variables:Atriyal fibrilasyon · yeni ilaçlar · Atrial fibrillation

Abstract

Atrial fibrillation (AF) is the most commonly encountered arrhythmia. Besides serious health problems and mortality incurred by patients, its complitacions bring about substantial economical losses. Among the most important health-related consequences are cerebrovascular and cardiovascular diseases. Therefore, convertion of AF to sinus rhythm and effective prevention from thromboembolic events are of particular importance. Despite the current availability of many rhythm control and anticoagulant medications, their efficacy and accessibility are not at a desired level. Due to adverse effects of antiarrhythmic drugs and narrow therapeutic range of anticoagulant drugs, there have been an increasing need for novel medications. There is ongoing research on the effects of many madications on AF. This paper reviews novel medicaitons in AF treatment.

Özet

Atriyum fibrilasyonu (AF) klinikte en sık görülen aritmi cinsidir. Hastalara getirdiği sağlık sorunları ve mortalite yanı sıra komplikasyonları ekonomik kayıplara neden olmaktadır. Sağlık sorunlarının başında serebrovasküler ve kardiyovasküler hastalıklar gelmektedir. Dolayısıyla AF’li hastaların ritmini yeniden sinüs ritmine döndürmek ve tromboembolik olaylara karşı etkin koruma sağlamak oldukça önemlidir. Bu amaçla, günümüzde kullanılmakta olan ritim düzenleyici ve pıhtı oluşumunu önleyici ilaçlar söz konusu ise de, bunlardan elde edilen yararlar ve kullanım kolaylığı istendiği düzeyde değildir. Hem antiaritmik ilaçların yan etkileri hem de antikoagülanların dar terapatik sınırları olması nedeniyle, AF tedavisinde yeni ilaçlara gereksinim duyulmaktadır. Bu amaçla birçok ilacın AF üzerindeki etkileri araştırılmaktadır. Bu derlemede AF’nin ilaç tedavisindeki yenilikler ele alınmıştır.

Keywords

Atriyal fibrilasyon yeni ilaçlar Atrial fibrillation novel drugs

🔖

Cite This Article

TÜRKMEN, Y., TÜRKOĞLU, C., YILDIZ, M. (2015). Novel Medications in the Treatment of Atrium Fibrillation. Koşuyolu Heart Journal, Cilt: 18 - Sayı: 3, 139–145. https://ajindex.com/articles/101279

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (13)

Uyarel H, Onat A, Yüksel H, Can G, Ordu S, Dursunoğlu D. Türk halkında kronik atriyal fibrilasyon insidansı, prevalansı ve mortalitesine ilişkin tahminler. Türk Kardiyol Dern Arş 2008;36:214-22
Corley SD, Epstein AE, DiMarco JP, Domanski MJ, Geller N, Greene HL, et al. Relationship between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation 2004;109:1509-13
Knobloch K, Brendel J, Rosenstein B, Bleich M, Busch AE, Wirth KJ. Atrial-selective antiarrhythmic actions of novel Ikur vs. Ikr, Iks, and IKAch class Ic drugs and beta blockers in pigs. Med Sci Monit 2004;10BR221-8
Haïssaguerre M, Jaïs P, Shah DC, Takahashi A, Hocini M, Quiniou G, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998;339:659-66
El-Armouche A, Boknik P, Eschenhagen T, Carrier L, Knaut M, Ravens U, et al. Molecular determinants of altered Ca2+ handling in human chronic atrial fibrillation. Circulation 2006;114:670-80
Blaauw Y, Gögelein H, Tieleman RG, van Hunnik A, Schotten U, Allessie MA. “Early” class III drugs for the treatment of atrial fibrillation: efficacy and atrial selectivity of AVE0118 in remodeled atria of the goat. Circulation 2004;110:1717-24
Bosch RF, Nattel S. Cellular electrophysiology of atrial fibrillation. Cardiovasc Res 2002;54:259-69
Yue L, Melnyk P, Gaspo R, Wang Z, Nattel S. Molecular mechanisms underlying ionic remodeling in a dog model of atrial fibrillation. Circ Res 1999;84:776-84
Courtemanche M, Ramirez RJ, Nattel S. Ionic targets for drug therapy and atrial fibrillation-induced electrical remodeling: insights from a mathematical model. Cardiovasc Res 1999;42:477-89
Peukert S, Brendel J, Pirard B, Strübing C, Kleemann HW, Böhme T, et al. Pharmacophore-based search, synthesis, and biological evaluation of anthranilic amides as novel blockers of the Kv1.5 channel. Bioorg Med Chem Lett 2004;14:2823-7
Matsuda T, Masumiya H, Tanaka N, Yamashita T, Tsuruzoe N, Tanaka Y, et al. Inhibition by a novel anti-arrhythmic agent, NIP-142, of cloned human cardiac K+ channel Kv1.5 current. Life Sci 2001;68:2017-24
Gögelein H, Brendel J, Steinmeyer K, Strübing C, Picard N, Rampe D, et al. Effects of the atrial antiarrhythmic drug AVE0118 on cardiac ion channels. Naunyn Schmiedebergs Arch Pharmacol 2004;370:183-92
Du YM, Zhang XX, Tu DN, Zhao N, Liu YJ, Xiao H, et al. Mo